How should Personalis balance the depth of genomic sequencing in its NeXT Platform against cost-effectiveness for customers?

Introduction

Balancing the depth of genomic sequencing in Personalis' NeXT Platform against cost-effectiveness for customers is a critical trade-off that directly impacts our value proposition and market position. This scenario involves weighing the benefits of more comprehensive genomic data against the need to maintain competitive pricing in the precision medicine market. I'll approach this analysis by examining the product's core features, stakeholder impacts, and potential outcomes of different sequencing depth strategies.

Step 1

Clarifying Questions (3 minutes)

• Based on the current market landscape, I'm thinking our positioning might be heavily influenced by competitors' offerings. Could you provide some context on how our sequencing depth compares to other players in the precision medicine space?

Why it matters: Helps understand our competitive advantage and market positioning Expected answer: We offer deeper sequencing than most competitors but at a higher price point Impact on approach: Would influence whether we focus on maintaining depth or reducing costs

• Considering our business model, I'm assuming the NeXT Platform is a key revenue driver. Can you confirm how significant it is to our overall business and what growth targets we have for it?

Why it matters: Aligns solution with business priorities and growth strategy Expected answer: NeXT Platform accounts for 60% of revenue with 25% YoY growth target Impact on approach: Would determine how aggressive we need to be in optimizing the trade-off

• From a user perspective, I'm curious about the primary use cases for our sequencing data. Are our customers primarily using it for research, clinical applications, or both?

Why it matters: Helps tailor the solution to meet specific user needs and value expectations Expected answer: Mix of research (60%) and clinical (40%) applications Impact on approach: Would influence whether to offer tiered solutions or focus on one primary use case

• Technically speaking, I'm wondering about the scalability of our current sequencing process. Is there a potential for significant cost reduction through technological advancements in the near future?

Why it matters: Informs whether short-term trade-offs might be mitigated by upcoming innovations Expected answer: Some improvements expected, but no major breakthroughs in the next 12-18 months Impact on approach: Would determine if we should make immediate changes or wait for tech advancements

• Regarding our development resources, I'm curious about our team's capacity to implement potential changes to the NeXT Platform. Do we have the bandwidth to make significant adjustments, or are we constrained?

Why it matters: Ensures proposed solutions are feasible given current resources Expected answer: Limited bandwidth due to other ongoing projects Impact on approach: Would influence the scope and timeline of any proposed changes